Metagenomi, Inc. (MGX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
MGX Chart
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.68 per share a year ago.
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.63 per share a year ago.
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Metagenomi, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 11,726 | $18,996.04 | $15,419.69 | -$3,576.35 | -18.83% |
 Craig Johnsen Fortitude Advisory Group LLC | 37,190 | $130,324.9 | $47,045.35 | -$83,279.55 | -63.9% |
| OM Olga Maltseva Catalio Capital Management LP | 528,993 | $1.91M | $663,886.21 | -$1.25M | -65.24% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 4 | $5.36 | $5.04 | -$0.32 | -5.97% |
| VT Vincent Tortorella Point72 (DIFC) Ltd | 134 | $198 | $168.84 | -$29.16 | -14.73% |
Metagenomi, Inc. (MGX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Metagenomi, Inc. ever had a stock split?
Metagenomi, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jian Irish CEO | NASDAQ (NGS) Exchange | 59102M104 CUSIP |
| US Country | 119 Employees | - Last Dividend | - Last Split | 9 Feb 2024 IPO Date |
Overview
Metagenomi Therapeutics, Inc. is an innovative in vivo genome editing company based in the United States, dedicated to developing curative genetic medicines. Founded in 2016 and headquartered in Emeryville, California, the company was originally known as Metagenomi, Inc. until its name change in January 2026. Metagenomi Therapeutics focuses on advanced therapeutic solutions for genetic disorders, enhancing patient outcomes by offering breakthrough treatments. Their lead development program, MGX-001, aims to provide long-lasting protection against bleeding and joint damage in individuals affected by hemophilia, targeting both adults and children.
In addition to its proprietary programs, the company has established a collaboration with Ionis Pharmaceuticals, Inc., working on multiple therapeutic targets. These collaborations reflect Metagenomi Therapeutics' commitment to harnessing cutting-edge genome editing techniques to revolutionize treatment modalities for various genetic conditions.
Products and Services
- MGX-001:
This is Metagenomi's lead development program, specifically tailored to address hemophilia. MGX-001 is designed to deliver curative outcomes by providing lifelong protection from bleeding events and joint damage in both pediatric and adult populations. The goal is to rectify the underlying genetic abnormalities in hemophilia patients, offering them a significant improvement in quality of life.
- Collaboration with Ionis Pharmaceuticals:
Through a strategic partnership with Ionis Pharmaceuticals, Metagenomi Therapeutics is expanding its research into several important therapeutic areas. Key targets in this collaboration include:
- Apolipoprotein C-III:
Targeting the treatment of hypertriglyceridemia, this program aims to reduce triglyceride levels and improve overall cardiovascular health.
- Transthyretin (TTR):
This program focuses on addressing transthyretin amyloidosis, a serious condition that can lead to multiple organ dysfunction. The goal is to develop a therapeutic that can stabilize or ameliorate the disease's progression.
- Angiotensinogen (AGT):
This initiative is directed at treating refractory hypertension, targeting the renin-angiotensin system to improve blood pressure regulation and reduce associated cardiovascular risks.
- Additional Programs:
Metagenomi Therapeutics is also exploring other innovative therapeutic areas through ongoing collaborations, enhancing their portfolio and contributing to the advancement of genetic medicine.
- Apolipoprotein C-III:
